Objective To compare prostatic artery embolisation (PAE) with transurethral resection of the prostate (TURP) in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia in terms of patient reported and functional outcomes. Design Randomised, open label, non-inferiority trial. Setting Urology and radiology departments of a Swiss tertiary care centre. Participants 103 patients aged ≥40 years with refractory lower urinary tract symptoms secondary to benign prostatic hyperplasia were randomised between 11 February 2014 and 24 May 2017; 48 and 51 patients reached the primary endpoint 12 weeks after PAE and TURP, respectively. Interventions PAE performed with 250-400 μm microspheres under local anaesthesia versus monopolar TURP performed under spinal or general anaesthesia. Main outcomes and measures Primary outcome was change in international prostate symptoms score (IPSS) from baseline to 12 weeks after surgery; a difference of less than 3 points between treatments was defined as non-inferiority for PAE and tested with a one sided t test. Secondary outcomes included further questionnaires, functional measures, magnetic resonance imaging findings, and adverse events; changes from baseline to 12 weeks were compared between treatments with two sided tests for superiority. Results Mean reduction in IPSS from baseline to 12 weeks was −9.23 points after PAE and −10.77 points after TURP. Although the difference was less than 3 points (1.54 points in favour of TURP (95% confidence interval −1.45 to 4.52)), non-inferiority of PAE could not be shown (P=0.17). None of the patient reported secondary outcomes differed significantly between treatments when tested for superiority; IPSS also did not differ significantly (P=0.31). At 12 weeks, PAE was less effective than TURP regarding changes in maximum rate of urinary flow (5.19 v 15.34 mL/s; difference 10.15 (95% confidence interval −14.67 to −5.63); P<0.001), postvoid residual urine (−86.36 v −199.98 mL; 113.62 (39.25 to 187.98); P=0.003), prostate volume (−12.17 v −30.27 mL; 18.11 (10.11 to 26.10); P<0.001), and desobstructive effectiveness according to pressure flow studies (56% v 93% shift towards less obstructive category; P=0.003). Fewer adverse events occurred after PAE than after TURP (36 v 70 events; P=0.003). Conclusions The improvement in lower urinary tract symptoms secondary to benign prostatic hyperplasia seen 12 weeks after PAE is close to that after TURP. PAE is associated with fewer complications than TURP but has disadvantages regarding functional outcomes, which should be considered when selecting patients. Further comparative study findings, including longer follow-up, should be evaluated before PAE can be considered as a routine treatment. Trial registration Clinicaltrials.gov NCT02054013.
To evaluate a single center's 10-year experience with emergency endovascular aneurysm repair (eEVAR) in 102 patients with ruptured abdominal aortoiliac aneurysms (RAAA). Data from 102 patients (mean age, 73 +/- 9 years) with RAAA treated by eEVAR from January 1998 to April 2008 were retrospectively reviewed. From January 2000, all patients were treated according to an intention-to-treat protocol. The only exclusion criterion was unsuitable anatomy. 31/102 patients had moderate shock and 14/102 patients had severe shock with a systolic blood pressure 20 mm Hg. The 30-day mortality for eEVAR was 13% (13/102). Technical success (defined as successful deployment of the endograft, absence of extravasation in the postprocedural contrast enhanced CT scan and hemodynamic stabilization) was 99% (101/102). Nineteen unstable patients (19%) required transfemoral supraceliac aortic balloon occlusion. ACS was detected and treated by OAT in 20 patients (20%). 16 type I, 26 type II and 1 type III endoleaks were detected on postoperative CT examination. Two patients had a combined type I and II endoleak. 11 patients were retreated for immediate correction of 10 type I and 2 type II endoleaks. 6 type I and 1 type III low-flow endoleaks were observed and resolved spontaneously within 30 days. Major 30-day morbidity was 35%. In this 102 patient contemporary series of eEVAR for RAAA, endografting proved to be safe with a 30-day mortality of 13%. Key components of this favorable outcome result were adequate preoperative diagnostic imaging, hypotensive hemostasis, selective transfemoral supraceliac aortic balloon occlusion, predominantly local anesthesia, detection and treatment of ACS, and attention to logistics. Widespread adoption of these treatment components is recommended.
Purpose To report midterm outcomes after urgent endovascular repair of ruptured pararenal or thoracoabdominal aortic aneurysms using multiple periscope and chim...